Lincoln Pharmaceuticals has reported that its net profit in the March quarter was flat at ₹12 crore on the back of strong demand.
Income was up 13 per cent at ₹183 crore (₹161 crore). EBITDA increased 5 per cent at ₹21 crore (₹20 crore).
The company has recommended a dividend of ₹1.80 a share for FY26.
Foreign Institutional Investors have steadily increased their stake in the company to 5.20 per cent while Domestic Institutional Investors holding was 1.08 per cent as of March-end. Greenx Wealth Multihorizons Opportunity Fund holds 1.07 per cent in the company while Rimo Capital Fund LP owns 1.33 per cent.
In FY26, the company reported a 7 per cent increase in net profit at ₹88 crore (₹82 crore) while income was up 9 per cent at ₹704 crore (₹646 crore). EBITDA increased 6 per cent to ₹131 crore (₹124 crore).
The company targets a revenue of ₹1,000 crore in the next three years, driven by business expansion into high-value product lines and entry into new markets. It aims to achieve a 15-18 per cent annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.
The company is also committed to expanding its global footprint while meeting diverse healthcare needs.
Munjal Patel, Director, Lincoln Pharmaceuticals, said the company remains focused on strengthening the product portfolio, expanding domestic and international presence and investing in research and manufacturing capabilities.
Backed by a debt-free balance sheet and strong fundamentals, the company remains confident of sustaining profitable growth and creating long-term value for stakeholders, he added.